Karyopharm Therapeutics Q2 2024 GAAP EPS $(0.20) Beats $(0.30) Estimate, Sales $42.786M Beat $36.179M Estimate
Karyopharm Therapeutics Q2 2024 GAAP EPS $(0.20) Beats $(0.30) Estimate, Sales $42.786M Beat $36.179M Estimate
karyopharm therapeutics 2024年第二季度的GAAP每股收益为$(0.20)，超过了$(0.30)的估计，销售额为4278.6万美元，超过了3617.9万美元的估计。
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 31.03 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $42.786 million which beat the analyst consensus estimate of $36.179 million by 18.26 percent. This is a 13.86 percent increase over sales of $37.579 million the same period last year.
Karyopharm Therapeutics（纳斯达克:KPTI）报告每股亏损$(0.20)，超过分析师预期的$(0.30)的33.33％。这是相对于去年同期每股亏损$(0.29)的31.03％增长。该公司报告季度销售额为4278.6万美元，超过分析师预期的3617.9万美元的18.26％。这是相对于去年同期的销售额3757.9万美元的13.86％增长。